BridGene Biosciences, Inc.

We are excited to announce that BridGene will present three groundbreaking posters at the American Association for Cancer Research (AACR) 2024 Annual Meeting in Barcelona, on October 25, 2024. The posters will showcase the company’s latest advancements in the development of covalent inhibitors for key oncogenic targets, including cMyc, ADAR1, and PAX8, each representing promising new treatment avenues for various cancers. Read more here：https://lnkd.in/dKpepT-A #CancerResearch #DrugDiscovery #Oncology #CovalentInhibitors #AACR2024 #BridGeneBiosciences #CancerTreatment #Biotech #SmallMoleculeDrugs #cMyc #ADAR1 #PAX8 #Immunotherapy #OncogenicTargets #HardToDrug #PharmaInnovation #TherapeuticAdvancements #DrugDevelopment #Biopharma #CancerInnovation #TumorMicroenvironment #ScientificResearch #Barcelona2024 #IMTACPlatform #RenalCellCarcinoma

Can't wait to meet you all!

Today, we are pleased to announce the acceptance of investigational New Drug (IND) application for our TEAD inhibitor BGC515 by Centre for Drug Evaluation (CDE) in China, following FDA’s IND approval in March. BGC515 is being developed for the treatment of cancers harboring genetic mutations in the Hippo signaling pathway. In June, we successfully initiated the first dosing of patient in the Phase I clinical trial of BGC515 in the United States. Our ongoing study will now expand to both the U.S. and China. Read more here: https://lnkd.in/gJUAfAr7 #DrugDevelopment #CancerResearch #TEADInhibitor #INDApproval #ClinicalTrials #Oncology #HippoPathway #Pharmaceuticals #Biotech #InnovationInMedicine #GlobalHealth #CancerTreatment #ResearchAndDevelopment #BGC515 #PrecisionMedicine

Today, we are excited to announce an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG). This new collaboration builds upon the partnership initiated in January 2024, focusing on the discovery of a highly selective oral SMARCA2 small molecule proteolysis targeting chimera (PROTAC). Under the expanded agreement, BridGene will leverage its PROTAC discovery engine in combination with Galapagos' expertise in selective ATPase small molecules. The collaboration aims to advance the molecule into a preclinical candidate, with Galapagos holding exclusive rights for further development and commercialization. Galapagos will provide BridGene with upfront and preclinical milestone payments, alongside additional payments based on clinical and commercial milestones, potentially bringing the total deal value to $159 million. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Read more here: https://lnkd.in/g7NyGm-m #BridGeneBiosciences #GalapagosNV #StrategicCollaboration #PrecisionOncology #PROTAC #SMARCA2 #DrugDiscovery #OncologyResearch #BiotechPartnership #InnovativeMedicine #CancerTreatment #TargetedTherapy #ClinicalResearch #Chemoproteomics #Biotechnology #Pharmaceuticals #DrugDevelopment #SmallMoleculeDrugs #ProteinDegradation #BiotechNews

We are thrilled to announce today that the first patient has been dosed in BridGene's Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through its cutting-edge chemoproteomic platform, IMTAC™. This milestone highlights the potential of BridGene’s innovative chemoproteomics approach. Our breakthrough in developing covalent small molecule drugs for “hard-to-drug” targets marks a significant advancement in our mission to bring new therapies to patients. We thank everyone who has worked so hard to make this possible. Thank you for being a part of our journey! Read more here: https://lnkd.in/gJUAfAr7 #Biotech #Pharma #ClinicalTrials #DrugDevelopment #TEADInhibitor #Chemoproteomics #Innovation #CovalentDrugs #HardToDrugTargets #IMTAC #BridGene #Healthcare #MedicalResearch #Biotechnology #NewTherapies #FirstPatientDosed #FirstPatientIn #ClinicalTrialMilestone #PatientEnrollment #PatientFirst #ClinicalTrialProgress #MedicalBreakthrough #PatientJourney #ResearchMilestone #TrialParticipant #PatientSuccess

In the interview with Clinical Trial Vanguard, our CEO Ping Cao discusses targeting “hard to drug” proteins that evade traditional small-molecule therapies due to their complex structures and functions BridGene, leveraging its proprietary IMTAC™ technology, seeks to innovate drug discovery by focusing on proteins essential in disease pathways yet difficult to target. This approach aims to pioneer new classes of medicines that can directly interact with and modulate protein functions, addressing significant unmet medical needs in areas like oncology and neurodegenerative diseases. Read more here: https://lnkd.in/dSHR5UU3 #DrugDiscovery #Biotechnology #ClinicalTrials #BridGeneBiosciences #IMTACPlatform #Oncology #NeurodegenerativeDiseases #InnovativeTherapies #HardToDrugProteins #PharmaceuticalResearch #MolecularBiology #ProteinTargeting #PrecisionMedicine #BioTechInnovation #MedicalResearch #CancerResearch

We are excited to announce that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the clinical study of its TEAD inhibitor BGC515 for the treatment of cancers harboring genetic mutations in the hippo signaling pathway.   "We are pleased to announce the FDA acceptance of our IND application for BGC515 and look forward to initiating this Phase I clinical study to evaluate the safety and efficacy profile of BGC515 in patients with advanced solid tumors," stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. "Discovered through our unique chemoproteomic platform, IMTAC™, the TEAD inhibitor BGC515 represents a significant breakthrough. The FDA's endorsement of this IND not only validates our innovative platform but also highlights a critical step forward in our mission to develop pioneering treatments for cancer patients. Learn more at https://lnkd.in/gzU2BnzF #BridGeneBiosciences #FDAApproval #BGC515 #CancerResearch #Innovation #HealthcareInnovation #ClinicalTrials #Biotech #Pharmaceuticals #Oncology #DrugDiscovery #Biotechnology #MedicalResearch #LifeSciences #TEADInhibitor #PrecisionMedicine #TherapeuticInnovation

Our CEO Ping Cao and EVP Irene Yuan are featured in the recent article, which sheds light on how BridGene Biosciences is leading the charge with our groundbreaking IMTAC™ platform, blending the strengths of Phenotypic Drug Discovery (PDD) and Target-Based Drug Discovery (TDD) to uncover novel compounds and their targets. IMTAC™ stands out by enabling the exploration of the entire proteome in live cells, a leap forward in identifying and validating new drug targets, especially within the realm of "undruggable" proteins. This approach broadens the therapeutic landscape and enhances the precision and effectiveness of drug development. The collaboration between BridGene and Takeda Pharmaceuticals, especially in tackling the complexities of neurodegenerative diseases, exemplifies the potential of such innovative approaches in addressing some of the most challenging medical conditions. As we look towards a future where drug discovery is more efficient, targeted, and capable of overcoming traditional barriers, the integration of technologies like IMTAC™ offers a beacon of hope. This article is a must-read for anyone interested in the cutting-edge of medical research and the promising avenues it opens for healthcare advancements! Read the full article here:https://lnkd.in/gEZ9CXFk #DrugDiscovery #Biotech #Innovation #Healthcare #Pharmaceuticals #Chemoproteomics #MedicalResearch #Neuroscience #Therapeutics #Biopharma #Chemoproteomics #Healthcare #Biotechnology #Pharmaceuticals

In a recent episode of the Empowered Patient Podcast by Karen Jagoda, discover how BridGene Biosciences is revolutionizing drug discovery with the IMTAC platform, as shared by Ping Cao on the Empowered Patient Podcast. This innovative technology enables targeting 'hard-to-drug' proteins, identifying over 4,000 new targets and leading with BGI-9004, a promising cancer inhibitor. Tackling the challenge of limited 'druggable' proteins, IMTAC, in partnership with Takeda, reveals potential in shadow-binding and transient protein pockets, a leap forward in precision therapy and treatment of neurodegenerative diseases. Join us in celebrating this breakthrough in medical science, paving new pathways in drug development. Find full podcast here: https://lnkd.in/gscSrFta #Innovation #DrugDiscovery #BridGeneBiosciences #HealthcareRevolution #EmpoweredPatientPodcast #PharmaceuticalInnovation #ProteomeResearch #CancerResearch #NeurodegenerativeDiseases #BiotechBreakthrough #MedicalScience #HealthcareTechnology #PrecisionMedicine #OncologyInnovation #Biopharmaceuticals

BridGene focus on cancer treatment is unwavering, and through the collaboration with Galapagos, we are venturing into new yet familiar territories. Our state-of-the-art IMTAC platform aims to target "hard-to-drug" molecules, reinforcing our position at the forefront of #OncologyInnovation. Stay tuned for more updates on this exciting journey! #BridGeneBiosciences #CancerResearch #InnovationInHealthcare #GalapagosCollaboration #Biotechnology #DrugDevelopment #OncologyInnovation #Pharmaceuticals #HealthcareTech #ClinicalTrials #MedicalResearch #BiotechInvestment #CancerTherapy #InnovativeMedicine #LifeSciences #TargetedTherapy #PartnershipInScience #CancerTreatmentAdvances #PharmaIndustry #SmallMolecules #TherapeuticDiscovery #BiotechNews #HealthcarePartnerships #FutureOfOncology Read more here: https://lnkd.in/gXJqHMZj